Back to Browse Journals » Clinical Ophthalmology » Volume 5

Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors

Authors Samuel K Houston, Yolanda Piña, Timothy G Murray, et al

Published 27 January 2011 Volume 2011:5 Pages 129—137


Review by Single-blind

Peer reviewer comments 3

Samuel K Houston1, Yolanda Piña1, Timothy G Murray1, Hinda Boutrid1, Colleen Cebulla2, Amy C Schefler1, Wei Shi1, Magda Celdran1, William Feuer1, Jaime Merchan3, Ted J Lampidis4
1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA; 2Department of Ophthalmology, The Ohio State University, Columbus, OH, USA; 3Division of Hematology/Oncology, Department of Medicine, 4Department of Cell Biology and Anatomy, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA

Purpose: The purpose of this study was to evaluate the effect of optimally timed combination treatment with angiogenic and glycolytic inhibitors on tumor burden, hypoxia, and angiogenesis in advanced retinoblastoma tumors.
Methods: LHBETATAG mice (n = 30) were evaluated. Mice were divided into 5 groups (n = 6) and received injections at 16 weeks of age (advanced tumors) with a) saline, b) anecortave acetate (AA), c) 2-deoxyglucose (2-DG), d) AA + 2-DG (1 day post-AA treatment), or e) AA + 2-DG (1 week post-AA treatment). Eyes were enucleated at 21 weeks and tumor sections were analyzed for hypoxia, angiogenesis, and tumor burden.
Results: Eyes treated with 2-DG 1 day post-AA injection showed a 23% (P = 0.03) reduction in tumor burden compared with 2-DG alone and a 61% (P < 0.001) reduction compared with saline-treated eyes. Eyes treated with 2-DG 1 week post-AA injection showed no significant decrease in tumor burden compared with 2-DG alone
(P = 0.21) and a 56% (P < 0.001) decrease in comparison with saline-treated eyes. 2-DG significantly reduced the total density of new blood vessels in tumors by 44% compared to saline controls (P < 0.001), but did not affect the density of mature vasculature.
Conclusions: Combination therapy with angiogenic and glycolytic inhibitors significantly enhanced tumor control. Synergistic effects were shown to be dependent on the temporal course of treatment, emphasizing optimal timing. 2-DG was shown to reduce the density of neovessels, demonstrating an antiangiogenic effect in vivo. As a result, angiogenic and glycolytic inhibitors may have significant potential as alternative therapies for treating children with retinoblastoma.

Keywords: retinoblastoma, adjuvant therapies, angiogenic inhibitors, glycolytic inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment

Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, Murray TG

Clinical Ophthalmology 2013, 7:193-198

Published Date: 22 January 2013

Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity

Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG

Clinical Ophthalmology 2012, 6:1739-1748

Published Date: 29 October 2012

Retinoblastoma treatment burden and economic cost: impact of age at diagnosis and selection of primary therapy

Aziz HA, LaSenna CE, Vigoda M, Fernandes C, Feuer W, Aziz-Sultan MA, Murray TG

Clinical Ophthalmology 2012, 6:1601-1606

Published Date: 4 October 2012

Intraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification

Parke III DW, Sisk RA, Murray TG

Clinical Ophthalmology 2012, 6:1347-1353

Published Date: 17 August 2012

Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification

Parke III DW, Sisk RA, Houston SK, Murray TG

Clinical Ophthalmology 2012, 6:925-931

Published Date: 18 June 2012

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ

Clinical Ophthalmology 2012, 6:817-830

Published Date: 29 May 2012

Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review

Shah NV, Houston SK, Murray TG, Markoe AM

Clinical Ophthalmology 2012, 6:447-452

Published Date: 20 March 2012

Can children undergoing ophthalmologic examinations under anesthesia be safely anesthetized without using an IV line?

Vigoda M, Latiff A, Murray T, Tutiven J, Berrocal A, Gayer S

Clinical Ophthalmology 2011, 5:503-508

Published Date: 20 April 2011

Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors

Y Piña, C Decatur, TG Murray, et al

Clinical Ophthalmology 2011, 5:337-343

Published Date: 7 March 2011

Clinical imaging and high-resolution ultrasonography in melanocytoma management

Daniel Gologorsky, Amy C Schefler, Fiona J Ehlies, et al

Clinical Ophthalmology 2010, 4:855-859

Published Date: 28 July 2010

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration

R Prince Davis, Amy C Schefler, Timothy G Murray

Clinical Ophthalmology 2010, 4:703-707

Published Date: 28 June 2010

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C

Clinical Pharmacology: Advances and Applications 2014, 6:61-62

Published Date: 27 March 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs

Rao S, Song Y, Peddie F, Evans AM

International Journal of Nanomedicine 2011, 6:1245-1251

Published Date: 20 June 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010